Table 1.
Baseline characteristics of patients
| Baseline characteristics | n = 54 | ||
|---|---|---|---|
| Age (years) | 45.5 (24–81) median 43 | ||
| Gender, male (%) | 34 (63) | ||
| Ethnicity (%) | 51 Asian (94 %) | ||
| 3 Caucasian (6 %) | |||
| Foreign-born | 46 (85 %) | ||
| Treatment naïve (n = 33) | ETV | TDF | ETV/TDF |
| 21 | 11 | 1 | |
| Treatment experienced (n = 21) | ETV 9 | TDF 12 | |
| Mean baseline HBV DNA of treatment-naïve patients (log10 IU/mL) | 7.62 (median 7.40, range 2.94–8.72) | ||
| Mean HBV DNA of patients treated with other NAs at time of switch to ETV or TDF (log10 IU/mL) |
7.69 (median 4.85, range undetectable-8.80) | ||
| Time to undetectable HBV DNAa (months) | 11.4 (median 9.0, range 0–33.4) | ||
| Time to HBeAg seroconversiona (months) | 21.0 (median 18.3, 1.5–61.6) | ||
| Consolidation period (months)b | 16.8 (median 14.0, 1.5–55.3) | ||
| Follow-up period after discontinuation of therapy (months) | 30.3 (median 31.1, 1.9–71.4) | ||
a
After initiation of ETV or TDF
b
Length of therapy after seroconversion